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V alvular heart disease (VHD) is highly prevalent in pa-tients with chronic kidney disease (CKD) and end-stagekidney disease (ESKD). This association with VHD is
prognostically important, being associatedwith poor outcomes
and higher mortality.1 The 5-year mortality rate among pa-
tients with at least mild aortic stenosis or mitral regurgitation
is more than 50% greater than in persons without CKD.1
Epidemiology
CKD. The ﬁrst detectable stage of VHD involvement in
CKD is calciﬁcation. The prevalence of aortic valve (AV) calciﬁc
abnormalities ranges from 28% to 85%.2 This prevalence is
signiﬁcantly higher than in the general population, where
calciﬁc aortic sclerosis is observed in about 25% of people $65
years and severe aortic stenosis (AS) is found in about 3% of
persons $75 years.3 AV calciﬁcation increases as estimated
glomerular ﬁltration rate (eGFR) decreases.4,5Kidney International (2019) 96, 836–849
TH Marwick et al.: CKD and valvular disease: a KDIGO conference report KD IGO execu t i ve conc lu s i onsAdministrative data from the US Renal Data System in
2017 showed that the prevalence of VHD diagnoses was 14%
among patients with CKD compared with 7% in the Medicare
survey of patients aged >65 years.6 More speciﬁcally, func-
tional evidence of aortic stenosis (as opposed to aortic
calciﬁcation) was present in 9.5% of patients with CKD,
compared with 3.5% of the general population (Figure 11),
with similar patterns for mitral regurgitation (43% vs. 24%),
mitral stenosis (2% vs. 1%), and aortic regurgitation (19% vs.
10%).1 Even when taking account of age, year of echocar-
diogram, race, sex, history of hyperlipidemia, hypertension,
congestive heart failure, diabetes mellitus, and prior coronary
revascularization, patients with CKD had a 1.2- to 1.3-fold
increased odds of aortic stenosis and 1.3- to 1.8-fold odds
of mitral regurgitation.1 The prevalence increased in parallel
with the progression to more advanced kidney disease
(Figure 2).1 In particular, aortic stenosis progressed more
rapidly among CKD patients; the decline in AV area was
estimated to progress at w0.2 cm2 per year in patients with
CKD, compared with w0.1 cm2 per year among patients
without CKD.7 The 2-year survival of patients with CKD who
had valvular disease was 72% compared with 86% in the
general population. Mortality was highest among patients
who had more advanced CKD, with a 2-year survival of 62%
in persons with CKD G4 and G5.
ESKD. The prevalence of diagnosed VHD in the United
States was found to be 14% in patients receiving hemodialysis
(HD), 12% in patients receiving peritoneal dialysis, and 7.4%
after renal transplantation.6 Further, the 2-year survival of
patients with VHD and ESKD was >30% lower compared0
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Figure 1 | Prevalence of left-sided valvular heart disease in patients w
(ESKD) compared with the general population.1
Kidney International (2019) 96, 836–849with persons without these conditions. Importantly, even in
the absence of signiﬁcant valvular dysfunction, the echocar-
diographic identiﬁcation of valvular calciﬁcation in 35% to
40% of patients with ESKD (Figure 3)8,9 was independently
associated with adverse cardiovascular outcomes.10
Aortic stenosis is the most prevalent valvular problem
among patients with ESKD. Its prevalence was found to be 6%
to 13%,2 and patients with ESKD had accelerated progression
of this problem.11 Aging and exposure duration of dialysis
predict the prevalence of AV disease in most studies, with an
association with increased calcium and phosphate levels
rather than lipid disorders.12 A change in AV area of –0.19
cm2/year has been reported among patients undergoing HD
(compared with –0.07 cm2/year among control subjects),7
and in the Action in Diabetes and Vascular disease: Pre-
terAx and DiamicroN Controlled Evaluation (ADVANCE)
trial, aortic calciﬁcation increased by 52% and mitral calciﬁ-
cation increased by 54% over a span of 1 year among HD
patients with secondary hyperparathyroidism who had calci-
ﬁcation at baseline.13 Over a 7-year follow-up of 110 patients
undergoing HD, the annual incidence of aortic stenosis was
3%.14 Signiﬁcant predictors for development of aortic ste-
nosis were older age, higher phosphate levels and calcium-
phosphorus product, and vitamin D levels.
Pathophysiology
There are important analogies between the development of
valvular and vascular disease in CKD. Even after adjustment
for age, dialysis duration, diabetes, and calcium-phosphate
product, mechanical and shear stress are importantMild Moderate Severe Mild Moderate Severe
ESKD CKD
Aortic regurgitation Aortic stenosis
ith chronic kidney disease (CKD) and end-stage kidney disease
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Figure 2 | Prevalence of left-sided valvular heart disease in patients with chronic kidney disease (CKD) of increasing severity. eGFR,
estimated glomerular ﬁltration rate. Adapted from Samad Z, Sivak JA, Phelan M, et al. Prevalence and outcomes of left-sided valvular heart
disease associated with chronic kidney disease. J Am Heart Assoc. 2017;6(10): pii: e006044.1 Copyright ª 2017 The Authors. Published on behalf
of the American Heart Association, Inc., by Wiley.
KDIGO execu t i ve conc lu s i ons TH Marwick et al.: CKD and valvular disease: a KDIGO conference reportcorrelates of valve calciﬁcation,15 as are inﬂammation
(assessed by C-reactive protein) and malnutrition (based on
serum albumin).16
Metabolic milieu. Calciﬁcation of the interstitial cells of
the valve leaﬂets (and the annulus and subvalvular apparatus
of the mitral valve) are the unifying pathophysiological fea-
tures of valvular stenosis and/or insufﬁciency secondary to
CKD and ESKD. The contributors to valve calciﬁcation in
CKD are numerous and complex (Figure 415). Although
multiple contributors (hyperphosphatemia, calcium-
phosphate product, parathyroid hormone, and b2-
microglobulin) have been identiﬁed, the exact contribution
of each component and their synergy remains to be under-
stood. Abnormal calcium and phosphate metabolism likely
predispose to the development of valvular calciﬁcation in
these patients.12 Low vitamin D levels are associated with
vascular calciﬁcation,17 and in elderly patients with aortic
stenosis, renal insufﬁciency, and low vitamin D levels, aortic
stenosis progression has been associated with secondary hy-
perparathyroidism.18 Excessive vitamin D supplementation is
also associated with valve calciﬁcation in animal models,19
although epidemiologic data in humans have focused more
on the association with vascular calciﬁcation. Warfarin use is
associated with calciﬁcation of the valves,20 peripheral
vasculature,21 and coronaries,22 and patients treated with
warfarin who are undergoing HD are prone to vertebral
fractures and mortality.23 Possibly as a consequence, warfarin
use is associated with increased mortality in persons with
ESKD.24 Amyloid protein deposition in calciﬁc AVs could be a
contributing factor.25 The available literature mostly pertains
to high-income regions, where degenerative calciﬁcation838predominates; data are more sparse from regions where
rheumatic heart disease is common. Furthermore, congeni-
tally abnormal valves, such as a bicuspid AV, can progress to
calciﬁcation and stenosis at a faster rate. Valve and aortic
calciﬁcation often co-exist and may occur at a young age,
being present in about a third of young (19- to 39-year-old)
patients with childhood-onset kidney disease who required
dialysis or kidney transplantation, often in association with
coronary artery calciﬁcation.26 Among patients undergoing
long-term dialysis, the number of calciﬁed valves was asso-
ciated with all-cause mortality and cardiovascular death; 1-
year all-cause mortality was 57% with calciﬁcation of both
aortic and mitral valves, 40% with either valve calciﬁed, and
15% for persons in whom neither was valve calciﬁed
(Figure 5).27
Hemodynamic milieu. Whereas increased shear stress has
been associated with the initiation and progression of aortic
stenosis, the speciﬁc role of arteriovenous ﬁstulae in the
progression of valve leaﬂet damage is unclear. However, ﬁstula
ﬂow may have other effects. The presence of a volume load
contributes to cardiac chamber enlargement, which may
worsen mitral and tricuspid valve regurgitation. Second, the
additional load of ﬁstula creation can lead to cardiac
decompensation.28
Mitral regurgitation has many potential causes in persons
with CKD and ESKD, but a critical distinction is between
functional (potentially reversible) and degenerative dysfunc-
tion. Mitral valve regurgitation in patients undergoing HD
may be partly or completely functional as a result of dilatation
of the left atrium and mitral annulus, both of which can be
related to volume overload.29Kidney International (2019) 96, 836–849
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Figure 3 | Prevalence of valvular calciﬁcation in the general
population and in patients with kidney disease.8,9 CKD, chronic
kidney disease; DM, diabetes mellitus; GP, general population; HD,
hemodialysis.
TH Marwick et al.: CKD and valvular disease: a KDIGO conference report KD IGO execu t i ve conc lu s i onsWhereas the most common sites of valvular involvement
are left-sided, right-sided valvular dysfunction, in particular
tricuspid regurgitation, may be equally common, and its
severity may signiﬁcantly vary, depending on the patient’s
volume status. Right-sided valve disease can be associated
with progression/deterioration of kidney disease, as well as
risk for right-sided endocarditis.
Clinical assessment
Preclinical valve disease. VHD guidelines recognize that
symptomatic valve disease is preceded by a potentially long
preclinical phase, during which the patient is unaware of
symptoms.30 This phase may be compounded by inactivity in
CKD. In addition, arteriovenous ﬁstula may contribute to the
challenges of assessing severity of VHD in patients undergo-
ing HD.31
Echocardiographic screening is widely used for the early
detection of VHD in persons with CKD. Use of this screening is
often based on the rationale that knowledge of the presence and
severity of valvular disease, left ventricular (LV) dysfunction, and
LV hypertrophy (LVH), along with the estimation of pulmonary
pressure, may all inﬂuence noncardiac aspects of care, including
dialysis management or transplant candidacy. Annual surveil-
lance has been suggested for persons with moderate VHD.
The application of screening ﬁndings to valve management
is more problematic. No medical intervention has been
shown to alter progression or outcomes of VHD. Nonetheless,
valve interventions may be considered in the absence of
symptoms when severe regurgitant lesions, or very severe
aortic stenosis (i.e., peak AV jet velocity >5.5 m/sec) or
rapidly progressive aortic stenosis (>0.3 m/s per year) are
identiﬁed from testing triggered by physical examinationKidney International (2019) 96, 836–849ﬁndings, or even when found coincidentally. It has been
proposed that patients with ESKD who have moderate aortic
stenosis are equivalent to “rapid progressors” who warrant a
yearly echocardiogram and monitoring for early symptoms.32
Symptomatic valve disease. The effects of CKD and ESKD
on the circulation can signiﬁcantly confound the evaluation of
VHD. Symptoms such as muscle weakness and fatigue may be
attributed to anemia and frailty. Dyspnea may be attributed to
pulmonary congestion due to ﬂuid overload. A high-output
state may be present as a result of anemia and magniﬁed by
the presence of an arteriovenous ﬁstula. Systolic murmurs
resulting from increased stroke volume, clinical evidence of
LVH and ﬂuid overload, and disturbances of vascular function
all may increase suspicion of valvular disease but also may
compromise its detection and the assessment of its severity.
Even after LVH or elevated biomarkers are identiﬁed on the
basis of an electrocardiogram or simple laboratory testing,
dyspnea may be attributed to heart failure with preserved
ejection fraction. Accordingly, imaging evaluation is essential;
the ﬁrst clinical imaging assessment for VHD is transthoracic
echocardiography, which should be readily accessible to cli-
nicians involved in the care of these patients.
Valvular regurgitation. Mitral and tricuspid regurgitation
are often functional and potentially reversible—worsened by
uncontrolled blood pressure and/or intravascular volume
expansion, both of which occur in persons with advanced CKD
and during the HD cycle. Echocardiography is best attempted
on a postdialysis day with the patient at “dry weight” and with
better blood pressure control. Although it seems intuitive that
this would ensure more accurate determination of LV mass and
systolic and diastolic function by minimizing variability in the
severity of ﬁlling pressures, pulmonary pressures, and valvular
regurgitation, speciﬁc evidence for this supposition is weak.33
Furthermore, no evidence exists regarding whether, in pa-
tients undergoing HD, adjustment and estimation of dry weight
using a combination of echocardiographic and biomarkers
could lead to improvement in valvular regurgitation severity
and symptoms.
Aortic stenosis. The assessment of aortic stenosis severity
requires consideration of both the AV and left ventricle, but it
is also important to remember that afterload is dependent not
only on the valve but also on blood pressure. Classically, se-
vere aortic stenosis is characterized by an AV area #1.0 cm2
and mean AV gradient$ 40 mm Hg,34 but these observations
may be discordant (Figure 6).35 Inconsistent severe aortic
stenosis grading by AV area (#1 cm2) with mean
gradient #40 mm Hg and maximum velocity #4 m/sec can
be seen in up to 30% patients with preserved left ventricular
ejection fraction, and for a left ventricle with normal func-
tion, the generation of a mean gradient of >40 mm Hg re-
quires a valve area closer to 0.8 cm.2,35 Discordance as a result
of technical factors may be particularly problematic in persons
with CKD and ESKD; body habitus not only can compromise
image quality but also make parallel alignment of the Doppler
beam and aortic stenosis jet more challenging than usual. Hy-
pertension is a common comorbidity and can increase the839
α
-SMA
Foam
 cellformation
m
odifier
O
xidative
Stretch
Macrophage
foam cell
Macrophage/
monocyte
Leukocyte
infiltration
TNF-α
RANKL
IL-1/-6
TGF-β
RAGE
DAMPs
TLR
VCAM-1
ICAM-1
OxLDL
O2–
qVIC
aVIC
NOTCH
Wnt/BMP
Apoptotic
cells
Runx2/Cbfa1
Sox9
EMT
oVIC
Ang II
Ang I
ACE
LDL
ACE
LDLMatrix vesicles
Calcification
Oscillatory
 flow
Fibrosa layer
Ventricularis layer
MMPs
Cathepsins
Collagen remodeling
Elastin fragmentation
Leaflet thickness
Amyloidosis
Shear stress:
• Bicuspid aortic valve
• Hyperdynamic circulation
  due to arteriovenous fistula
Blood factors:
•   Calcium–phosphate product
• Hyperparathyroidism
• β2 microglobulin
• Vitamin K antagonists
Figure 4 | Molecular, cellular, and biomechanical mechanisms of calciﬁed aortic valve disease. In addition to generic factors related to
valve calciﬁcation (shear stress, inﬂammation, adhesion molecules, and lipids), chronic kidney disease (CKD)–speciﬁc factors are suspected.
ACE, angiotensin-converting enzyme; Ang I/II, angiotensin I/II; aVIC, activated valve interstitial cell; BMP, bone morphogenetic protein; DAMPs,
damage-associated molecular patterns; EMT, endothelial-to-mesenchymal transition; ICAM-1, intracellular adhesion molecule-1; IL-1/-6,
interleukin-1/-6; LDL, low-density lipoprotein; MMPs, matrix metalloproteinases; oVIC, osteogenic valve interstitial cell; OxLDL, oxidized low-
density lipoprotein; qVIC, quiescent valve interstitial cell; RAGE, receptor for advanced glycation endproducts; RANKL, receptor activator of
nuclear factor-kB ligand; Runx2, runt-related transcription factor 2; a-SMA, alpha smooth muscle actin; TGF-b, transforming growth factor-b;
TLR, toll-like receptor; TNF-a, tumor necrosis factor-a; VCAM-1, vascular adhesion molecule-1. Adapted with permission from Yutzey KE, Demer
LL, Body SC, et al. Calciﬁc aortic valve disease: a consensus summary from the Alliance of Investigators on Calciﬁc Aortic Valve Disease.
Arterioscler Thromb Vasc Biol. 2014;34:2387–2393.15 Copyright ª 2014 American Heart Association, Inc. Available at: https://www.ahajournals.
org/journal/atvb.
KDIGO execu t i ve conc lu s i ons TH Marwick et al.: CKD and valvular disease: a KDIGO conference reportcomplexity of aortic stenosis assessment. Calculation of the
valve area is based on the continuity equation (based on the
assumption that ﬂow through the outﬂow tract and AV are
equal), and this is subject to error when septal hypertrophy
invalidates the assumption that the LV outﬂow tract is circular.
Because all stenotic indices, including gradients, are ﬂow
dependent, the transvalvular gradient may overestimate AV area
and underestimate stenosis severity in the presence of a high-
ﬂow state, such as in a patient with arteriovenous ﬁstula.
Temporary arteriovenous ﬁstula compression might be required
to decrease transvalvular ﬂow and to better evaluate aortic
stenosis severity.36
Patients with signiﬁcant aortic stenosis and reduced
stroke volume typically have low gradient (i.e., <40
mm Hg). This is a heterogeneous group (Table 1),37 and it
is important to correctly classify whether the problem is840the ventricle, the AV, or a combination of both. When
reduced stroke volume is due to low ejection fraction, this
is known as “classical” low-ﬂow low-gradient stenosis
(Figure 7). The response to low-dose dobutamine stress
can help elucidate whether the primary problem is aortic
stenosis (reduction of valve area remains severe and
gradient increases in parallel to stroke volume) or “pseu-
dostenosis” (increasing stroke volume produces increased
valve area and no increment of gradient). Moreover, the
presence of LV contractile reserve suggests potential
improvement of LV systolic function after surgical aortic
valve replacement (AVR). Nonetheless, this may be less
relevant in the transcatheter AVR (TAVR) era; in the True
or Pseudo-Severe Aortic Stenosis (TOPAS)–TAVR registry,
contractile reserve status did not predict outcomes and/or
LV ejection fraction recovery after TAVR.38Kidney International (2019) 96, 836–849
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Figure 5 | Prognostic signiﬁcance of valvular calciﬁcation in end-stage kidney disease. Both the presence and the extent of calciﬁcation
are associated with overall (a,c) and cardiovascular outcome (b,d). Republished with permission of the American Society of Nephrology from
the Journal of the American Society of Nephrology. Cardiac valve calciﬁcation as an important predictor for all-cause mortality and
cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. Wang AY, Wang M, Woo J, et al. J Am Soc Nephrol.
2003;14:159–168.27 Copyright ª 2002. Permission conveyed through Copyright Clearance Center, Inc.
TH Marwick et al.: CKD and valvular disease: a KDIGO conference report KD IGO execu t i ve conc lu s i onsThe ﬂow dependence of the valve gradient also underlies
“paradoxical” low-ﬂow low-gradient stenosis, i.e., the
mismatch between reduced valve area and a low gradient in
the setting of a normal ejection fraction and reduced stroke
volume (Figure 7).39 This entity characteristically involves
elderly persons and may be considered as a combination of
aortic stenosis with heart failure with preserved ejection
fraction.
Among patients with poor visualization of the AV, high
cardiac output, and/or discrepancies between AV area and
gradients, 3 other pieces of evidence may be of value. The ﬁrst
is the dimensionless severity index—a ratio between the
proximal (LV outﬂow tract) and the distal (AV) velocities to
cancel out the potential high-ﬂow state. A dimensionless
severity index of <0.25 (i.e., a 4-fold acceleration in velocity)
implies severe aortic stenosis. The dimensionless severity in-
dex is not only more reproducible than AV area40 but also less
variable,41 and importantly is linked with outcomes.42 The
second piece of evidence is direct evaluation of valve structure
and function with transthoracic echocardiography, trans-
esophageal echocardiography for left-sided valves, or retro-
spectively gated computed tomography angiography. The
third piece of evidence is the use of a ﬂow-independent metricKidney International (2019) 96, 836–849for severe aortic stenosis, based on AV calciﬁcation from
noncontrast gated chest computed tomography. The cutoff
AV calcium score for severe aortic stenosis ($2000 Agatston
units in men and $1200 in women) identiﬁes severe aortic
stenosis with an area under the curve $0.89,
sensitivity$86%, and speciﬁcity$79%.43 Sex-speciﬁc cutoffs
(>2000 Agatston units in men and >1300 in women)43
recently were shown to be more closely associated with out-
comes than echocardiographic parameters of aortic stenosis
severity in a large multicenter registry.44 Furthermore, the
additional information obtained from a computed tomogra-
phy study (severity of calciﬁcation of the valves, aortic
annulus, aorta, mitral annulus, and coronary vessels) is
important for procedural planning and for the assessment of
other potential complications that can arise from valve
interventions.
Mitral annular calciﬁcation. Similar to aortic stenosis and
aortic calciﬁcation, mitral annular calciﬁcation (MAC) shares
biological links with atherosclerosis and is very common in
patients with CKD45,46 and aortic stenosis. MAC is particu-
larly prevalent and extensive in patients undergoing HD.
MAC progression appears to be more closely associated with
the extent of baseline MAC and its inﬂammatory component,841
Table 1 | Contributors to low aortic valve gradients in aortic
stenosis
Reduced forward
stroke volume
LV abnormalities  Concentric remodelling
(LVH, cardiac amyloidosis)
 Reduced diastolic ﬁlling
Rhythm  Atrial ﬁbrillation
Reduced transmitral
ﬂow
 RV dysfunction
 Tricuspid regurgitation
 Mitral stenosis
Mitral regurgitation
Reduced
transvalvular
ﬂow rate
Increased ejection
time
Paced rhythm
LV, left ventricular; LVH, left ventricular hypertrophy; RV, right ventricular.
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Figure 6 | Discordance of gradient and valve area in aortic
stenosis. Reprinted with permission from Minners J, Allgeier M,
Gohlke-Baerwolf C, et al. Inconsistencies of echocardiographic
criteria for the grading of aortic valve stenosis. European Heart
Journal. 2008;29:1043–1048, by permission of the European Society
of Cardiology. All rights reserved. Copyright ª The Author 2007.35
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eGFR.47 The presence of MAC has been associated with mitral
regurgitation, stenosis, or mixed valvular disease. In addition,
MAC is associated with greater cardiovascular risk, and higher
risk for endocarditis, and atrial arrhythmias. Mitral in-
terventions (either surgical or transcatheter therapies) remain
challenging with high morbidity and mortality in the pres-
ence of MAC.48
Management
Prevention. Valvular calciﬁcation is an important
contributor to VHD among patients with CKD and ESKD,
particularly among patients with rapidly progressive aortic
stenosis.
Delaying the onset of valvular calciﬁcation may be a
means of delaying the development or progression of
VHD. Unfortunately, there is a dearth of high-quality ev-
idence of beneﬁt from this strategy in randomized trials.
The Action in Diabetes and Vascular disease: PreterAx and
DiamicroN Controlled Evaluation (ADVANCE) study
tested the use of a calcimimetic drug (cinacalcet, Amgen,
Thousand Oaks, CA) in patients with ESKD. The study
reported signiﬁcant retardation of the progression of
valvular calciﬁcation among patients randomized to cal-
cimimetic therapy and low-dose vitamin D supplementa-
tion.13 Cinacalcet also may retard progression of LVH in
this population.49 Whether there could be a beneﬁcial and
protective effect of cinacalcet on the progression of aortic
stenosis and hypertrophic response is unknown. The use
of cinacalcet at least merits consideration for the treatment
of patients with secondary hyperparathyroidism and842rapidly progressive aortic stenosis and consideration for a
speciﬁc clinical trial.
Despite the analogies between vascular and valvular injury,
statin therapy has been ineffective in preventing the pro-
gression of aortic stenosis in the general population in 2
landmark trials.50,51 Nonetheless, there may be a difference in
the effect of low-density lipoprotein cholesterol control be-
tween AV sclerosis and stenosis, implying the intervention
was too late. Alternatively, the type of intervention may have
been inappropriate; the ongoing Study Investigating the Effect
of Drugs Used to Treat Osteoporosis on the Progression of
Calciﬁc Aortic Stenosis (SALTIRE-2) trial (n ¼ 150) is
randomizing patients with aortic stenosis to alendronate
versus denosumab (NCT02132026).
Medical management. Medical therapy options for the
management of symptomatic valve disease are limited. Con-
trol of volume status with diuretics and hemoﬁltration may
control congestive symptoms in the setting of regurgitant
valve lesions and reduce functional regurgitation by allowing
reverse remodeling. For patients undergoing HD, echocardi-
ography could improve the estimation and adjustment of dry
body weight, preventing the progression of chamber dilation
and LV hypertrophy.52 Whether this could also improve the
severity of valvular regurgitation remains to be seen. Based on
modest evidence in the general population, vasodilators are
used to unload the left ventricle in the presence of aortic
regurgitation or functional mitral regurgitation, although
their use with primary mitral regurgitation is controversial.53
Among patients undergoing HD in the setting of signiﬁcant
aortic stenosis, large volume removal over a short period and
rapid changes in blood pressure should be avoided.
General considerations of surgical management. Valvular
interventions are commonly considered in CKD, and knowledge
of the speciﬁc challenges should inform access to nephrology
expertise at cardiothoracic centers. Nonetheless, among patients
with CKD and ESKD, evidence about whether, when, or how to
intervene remains limited. Most data are derived from retro-
spective registry analyses,54 and comparisons have been per-
formed with propensity score matching. Relevant considerationsKidney International (2019) 96, 836–849
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Figure 7 | Distinction of classical and paradoxical low-ﬂow, low-gradient aortic stenosis (aortic stenosis). Dobutamine
echocardiography may be useful to distinguish true and pseudostenosis in low-ﬂow low-gradient aortic stenosis with reduced ejection
fraction. AS, aortic stenosis; AV, aortic valve; CT, computed tomography; EF, ejection fraction; LFLG, low-ﬂow, low-gradient; LV, left ventricular;
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surgical and percutaneous valve delivery, consideration of goals
of care (symptomatic beneﬁts and survival), and caution
regarding the potential side effects of warfarin (not only
bleeding, but also the risk of calciphylaxis and calciﬁcation). In
the past decade we have seen the rapid development of TAVR
but also parallel improvements in cardiothoracic surgery (e.g., in
perfusion, valves, surgical technique, and approaches). Calciﬁ-
cation, especially annular calciﬁcation, poses speciﬁc issues for
surgery and percutaneous intervention and is the major differ-
ence between CKD/ESKD and non-CKD.
Among patients with mild to moderate CKD, the beneﬁts
and risks of valve surgery are similar to those for the general
population. However, the risks in persons with advanced
CKD and ESKD are greater (Figure 8), with increasing
mortality with worsening eGFR.55 Despite the fact that out-
comes of valve survival are poor in persons with ESKD, no
studies have been performed that compare intervention with
palliative or medical management.
AV replacement. In persons with early stage CKD,
younger patients, and potential transplant candidates, man-
agement strategies for valvular disease should follow theKidney International (2019) 96, 836–849guidelines in the general population. These guidelines include
surveillance of both the progression of symptoms and the
progression of the severity of VHD, leading eventually to valve
intervention.56 On the other hand, among older patients,
speciﬁcally those with comorbidity, and patients with
advanced CKD and ESKD, survival is markedly reduced. This
information is important, because a median survival >2 years
is considered the threshold for cost-effectiveness of TAVR in
the general population.57
Valve intervention in persons with CKD has been studied
most frequently for aortic stenosis, albeit in post hoc or reg-
istry analyses, with attempts to minimize selection bias by
propensity matching. The currently available interventions
are surgical AVR (biological or mechanical) and TAVR. De-
velopments of both treatments in the past 15 years (particu-
larly TAVR) have extended valve replacement to patients with
advanced age and with comorbidities (including CKD/ESKD)
previously considered inoperable. However, data on the
management of VHD in CKD and ESKD are sparse, and no
studies have compared interventional treatment with medical
management, at a time when conservative (nondialysis)
management of patients with CKD is gaining popularity.58843
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complication rates such as major bleeding and reoperation
and mortality when comparing patients with moderately
reduced kidney function (GFR between 30–60 ml/min per
1.73 m2) versus those without kidney disease.59 Mortality
after surgical AVR increases with worsening eGFR
(Figure 8).55 Patients undergoing HD represent a more
challenging group, given their higher burden of comorbid-
ities. Although there has been an increase in the utilization of
surgical AVR between 2005 and 2014 for these patients, along
with a decrease in their mortality over time, in-hospital
mortality in these patients remains twice that of their non-
HD counterparts (8.1% vs. 3.9%, P < 0.001) even after
propensity matching.60 Recent reviews61 have emphasized the
role of biological and mechanical valves62; the current
consensus is that survival is similar.63 The On-X mechanical
AVR has lower anticoagulation requirements and may beTable 2 | Mortality in patients with reduced GFR after TAVR66
CKD G1-G2
‡60 ml/min
per 1.73 m2
CKD G3
30–60 m
per 1.7
30-d mortality 6.0 7.
Late (>30-d) mortality 21.4 25.
Cardiovascular 12.1 14.
Noncardiovascular 9.3 11.
CKD, chronic kidney disease; GFR, glomerular ﬁltration rate; TAVR, transcatheter aortic v
Data are presented as percentages.
Adapted with permission from Allende R, Webb JG, Munoz-Garcia AJ, et al. Advanced ch
insights on clinical outcomes and prognostic markers from a large cohort of patients. Eu
Cardiology. Copyright ª The Author 2014.66
844attractive in persons with CKD, but no analysis of this valve
has been performed in persons with CKD.64
TAVR represents a potentially less invasive alternative for
management of aortic stenosis in persons with CKD. Similar
to what was seen with surgical AVR, there are parallel in-
creases in risk associated with advanced CKD in patients
undergoing catheter-based interventions. Speciﬁcally, there is
a graded response of TAVR outcomes, in particular higher
mortality and complication rates with progressive CKD
(Table 2).65–71 In the Placement of Aortic Transcatheter
Valves (PARTNER) trial, there was a 10.7% 30-day and 34.4%
1-year mortality for patients with severe CKD.72 Compared
with patients who were not undergoing dialysis, patients with
ESKD were younger (76 vs. 83 years; P < 0.01) and had
higher rates of comorbidities leading to a higher Society of
Thoracic Surgeons predicted risk of mortality (median 13.5%
vs. 6.2%; P < 0.01). Likewise, patients undergoing dialysis
had a higher 1-year mortality (37% vs. 19%; P < 0.01) and a
higher rate of major bleeding (1.4% vs. 1.0%; P ¼ 0.03) in
3053 (4.2%) of >72,000 patients in the Society of Thoracic
Surgeons/American College of Cardiology Transcatheter Valve
Therapies registry.73 Analogous ﬁndings were identiﬁed in
another group of dialysis patients undergoing TAVR, who had
a 1-year mortality rate of 39%, compared with a 17.5% rate in
those with CKD G3a (eGFR between 45–59 ml/min per 1.73
m2).65 This mortality rate appears to be further ampliﬁed by
the presence of atrial ﬁbrillation, with 1-year mortality rates
as high as 71%.66 The development of acute kidney injury in
the peri-procedural TAVR setting is also associated with worse
outcomes,74,75 especially if post-TAVR HD is required.76
Thus, while clear evidence exists that TAVR outcomes have
been improving as the technique has become more estab-
lished (rates of TAVR are increasing rapidly and have sur-
passed surgical AVR in some jurisdictions77), there is a
persistent signal of adverse outcomes in patients with ESKD.
Thus, whereas the procedure is not necessarily futile—a small
study has documented better 1-year outcomes for dialysis
patients with severe aortic stenosis undergoing surgical or
transcatheter aortic valve repair compared with balloon aortic
valvuloplasty78—there are possibilities for harm, especially in
the presence of comorbid disease.79
The longevity of TAVR and biological prostheses in pa-
tients with advanced CKD and ESKD is an important sourcea-G3b
l/min
3 m2
CKD G4
15–30 ml/min
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<15 ml/min per
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7 10.4 11.9
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0 20.0 11.9
1 12.5 32.2
alve replacement.
ronic kidney disease in patients undergoing transcatheter aortic valve implantation:
ropean Heart Journal. 2014;35:2685–2696, by permission of the European Society of
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Given the limited survival in this group of patients, the long-
term TAVR prosthesis durability and whether early degener-
ation can occur remain unanswered questions, but at least at
1 year, results appear promising for durability.66 Results of
attempts to compare TAVR with surgical AVR must be viewed
carefully. Overall, surgical AVR is performed in younger and
ﬁtter patients and in those undergoing coronary artery bypass
graft, whereas TAVR is reserved for inoperable, older patients
with comorbidity. Propensity score matching compares the
“best” of the TAVR group with the worst of the surgical AVR
group. Nonetheless, limited, nonrandomized, propensity-
matched data comparing surgical versus transcatheter AVR
for patients with advanced CKD suggest that apart from a
higher postprocedural need for a pacemaker with TAVR,
mortality and periprocedural complications are signiﬁcantly
less common with that approach.80 In particular, the potential
need for dialysis appears to be lower among patients with
advanced CKD receiving TAVR versus surgical AVR.81 How-
ever, despite the best efforts, the development of acute kidney
injury on top of CKD requiring dialysis is a real risk that is
associated with high short-term mortality.67,81
A third of patients with CKD G4 who undergo valve
replacement will be dead within 1 year, with roughly 1 in 6
requiring dialysis. In patients with CKD G5, more than one
third will require kidney replacement therapy within 30 days;
nearly two thirds will require kidney replacement therapy at 1
year. These data provide the context for discussion about
goals of care and inform shared decision making in elderly
patients with advanced CKD.67 Nonetheless, functional class
and symptomatic improvements are noted across all the CKD
stages and even in those undergoing HD.66,69
Surgery for mitral regurgitation. The presence of kidney
disease with severe mitral regurgitation leads to an almost 3-
fold increase in mortality.1 Advanced CKD is associated with
increased risk of side effects and mortality with either mitralKidney International (2019) 96, 836–849replacement or repair (Figure 982). Among the 86,563 mitral
interventions reported by Vassileva et al.,82 1480 patients were
undergoing dialysis. Dialysis-dependent patients had a lower
propensity for mitral repair (44.6% vs. 61.5%; P ¼ 0.0010;
adjusted odds ratio, 0.69; 95% conﬁdence interval, 0.61–
0.78). No difference was reported in procedural success be-
tween repair and replacement in patients undergoing dialysis.
For all mitral operations, 30-day mortality was 9.3%
(compared with 2.3% for patients not undergoing dialysis),
and 30-day mortality or major morbidity was 40.9% (vs.
15.9% for patients not undergoing dialysis).
Of particular interest is the possibility of percutaneous
transcatheter mitral valve repair with the MitraClip device
(Abbott Vascular, Menlo Park, CA), in select candidates. The
observation of improvement in kidney function after device
implantation has generated the hypothesis that hemodynamic
improvements resulting after percutaneous mitral valve repair
may improve kidney function.83 Percutaneous mitral valve
repair has been reported to have a high mortality at 1 year in
patients with CKD G4–G5.84 Further studies of kidney
function after cardiac interventions and the inﬂuence on
clinical outcome are needed.
Endocarditis
The risk of endocarditis increases with each step in the pro-
gression of CKD, with a dramatic increase among patients
receiving HD.85 In the latter group, the annual risk of bac-
terial endocarditis is almost 1%, especially during the ﬁrst 5
months of HD.85 This is approximately 100 times that of the
unselected general population (including other high-risk
groups). The risk is greatest among patients with ESKD and
prosthetic or structurally abnormal valves, who have an HD
catheter as their dialysis access.86 Although infection of access
grafts is nearly 10 times greater than the ﬁstula infection
rate,87 it is not known that this is matched by differences in
the frequency of endocarditis. Endocarditis involving TAVR845
Table 3 | Evidence gaps and future needs
Topic Research questions
General  Analysis of surrogate outcomes in patients with valvular heart disease with CKD/ESKD—speciﬁcally, regression of
LVH following intervention
 Use of frailty scores in perioperative evaluation
 The impact of CKD/ESKD on structural valve deterioration
 Incidence of valve disease among CKD
 Role of dialysis mode (HD vs. PD) and kidney transplantation on valve disease
 Studies of valve disease that address feeling better rather than living longer
Aortic valve  Relation between aortic stenosis and risk of sudden death in ESKD
 Trials comparing TAVR, SAVR in CKD, and between TAVR/SAVR and medical management in patients with advanced
CKD and ESKD
 Timing of AVR in CKD to delay or prevent dialysis
 Attempts to target inﬂammation (and senescence) in CKD to prevent aortic valve disease
 Trials of medical therapies, including cinacalcet, to alter the progression of valvular calciﬁcation
 Trials of TAVI vs. SAVR on left ventricular mass regression in CKD/ESKD
Mitral valve disease  Analysis of the prevalence of mitral valve disease, interventions, and outcomes in CKD/ESKD
 Understand the determinants of MAC and its progression
 A study of intervention (surgical or percutaneous) vs. medical management of mitral regurgitation
 A study for management (surgical or percutaneous) of patients with advanced MAC and mitral valvular disease.
Clinical trials (all valves)  RCT in valvular heart disease interventions for patients with CKD (e.g., surgical bioprosthesis vs. mechanical [On-X])
Right-sided heart disease  Determinants of right-sided valvular abnormalities and the association of secondary right heart problems, including
pulmonary hypertension, right ventricular failure and tricuspid regurgitation on outcomes
 Additional epidemiological studies on right sided heart disease
Calciﬁcation  Factors affecting progression of valvular calciﬁcation in CKD, ESKD
 Best methods to monitor progression (CT, PET-CT, echocardiography vs. biomarkers)
Endocarditis  Subacute bacterial endocarditis prophylaxis
 Treatment approaches with antibiotics alone vs surgery
 Role of PET-CT
AVR, aortic valve replacement; CKD, chronic kidney disease; CT, computed tomography; ESKD, end-stage kidney disease; HD, hemodialysis; LVH, left ventricular hypertrophy;
MAC, mitral annular calciﬁcation; PD, peritoneal dialysis; PET-CT, positron emission tomography–computed tomography; SAVR, surgical aortic valve replacement; TAVR,
transcatheter aortic valve replacement.
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time of 5 months from TAVR, with a mortality rate of 36%.
The pattern of organisms identiﬁed is also unlike the general
population, with a preponderance of staphylococcal infections in
patients with ESKD.85 This phenomenon likely reﬂects
contamination by skin organisms in patients with i.v. access.
Avoidance of dialysis catheters is sensible and is a strong argu-
ment for preplanned permanent dialysis access in patients
approaching ESKD. Patients who have ESKD and require valve
replacement after treatment for endocarditis have a very poor
outcome, with a 1-year mortality of about 50%.86
In the evaluation of suspected endocarditis, particularly
involving prosthetic valves, transesophageal echocardiography
is essential and should be readily accessible in the manage-
ment of patients receiving HD and other patients with ESKD
receiving kidney replacement therapy. Repeat transesophageal
echocardiography may need to be considered in patients
whose echocardiographic ﬁndings are negative or indeter-
minate, but clinical suspicion remains high. In addition, a
growing body of literature on the potential role of positron
emission tomography fused with computed tomography is
available to help in the diagnosis of such cases.89
Conclusions
The prevalence of VHD is increased in patients with CKD
compared with the general population, especially in patients846with ESKD. In addition, the progression of VHD is faster in
patients with CKD/ESKD when compared with the general
population. The primary pathophysiological process involves
calciﬁcation of valves and associated structures. While it is
well established that VHD is associated with increased mor-
tality, the optimal management of the excess CV risk due to
valvular (rather than coronary artery or cardiomyopathic)
heart disease in advanced CKD and ESKD remains unclear.
Most of the literature is focused on aortic stenosis, with
limited data on other valvular abnormalities. The role of
medical therapies, such as cinacalcet, on development and
progression of CKD-associated valve disease requires further
study. Several evidence gaps and needs have been identiﬁed by
the conference attendees that should help in the future design
of studies to improve the understanding of diagnosis and
management of VHD in this special population (Table 3).APPENDIX
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